Channel Therapeutics Corporation
CHRO · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 0% | – | – | 50% |
| R&D Expenses | $0 | $1 | $0 | $0 |
| G&A Expenses | $0 | $3 | $2 | $2 |
| SG&A Expenses | $20 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$12 | $0 | $0 | -$1 |
| Operating Expenses | $7 | $3 | $2 | $1 |
| Operating Income | $0 | -$3 | -$2 | -$2 |
| % Margin | 0% | – | – | -195.6% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$17 | -$3 | -$2 | -$2 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$16 | -$3 | -$2 | -$2 |
| % Margin | -219.3% | – | – | -206.5% |
| EPS | -5.3 | -5.38 | -0.32 | -0.34 |
| % Growth | 1.5% | -1,581.2% | 5.9% | – |
| EPS Diluted | -5.3 | -5.38 | -0.32 | -0.34 |
| Weighted Avg Shares Out | 3 | 1 | 6 | 6 |
| Weighted Avg Shares Out Dil | 3 | 1 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $2 | -$1 |
| EBITDA | -$14 | -$3 | -$0 | -$2 |
| % Margin | -194.2% | – | – | -237.6% |